Eli Lilly Dominates Q1 2025 Branded Pharma Earnings with 55.5% Revenue Surge; Merck, Supernus Post Mixed Results
核心洞察
Eli Lilly reported Q1 revenues of $19.8 billion, up 55.5% year-on-year, beating analyst estimates by 13.7% and posting the fastest revenue growth among branded pharma peers.
Merck (搜索) delivered revenues of $16.29 billion, a 4.9% increase year-on-year, exceeding analyst expectations by 3% with a beat on EPS estimates.
Supernus Pharmaceuticals posted revenues of $207.7 million, up 38.6% year-on-year, driven by a 56% increase in combined growth product revenues, though EPS estimates were significantly missed.
Eli Lilly delivered a standout performance in the first quarter of 2025, reporting revenues of $19.8 billion — a 55.5% year-over-year increase that outpaced analysts' consensus estimates by 13.7%. The results cemented the company's position as the top performer among the 10 branded pharmaceuticals stocks tracked this earnings season, achieving both the largest analyst estimate beat and the fastest revenue growth across the peer group. The market responded decisively, with Eli Lilly shares climbing 29.6% to 34.9% since reporting, reaching approximately $1,103 to $1,149 per share.
The broader branded pharmaceuticals industry posted mixed results for Q1, with aggregate revenues surpassing consensus estimates by 3.6%. Share prices across the group have remained relatively stable on average, though individual company performance varied considerably.
Merck (搜索) Posts Solid Growth Driven by Diversification Strategy
Merck (搜索) reported Q1 revenues of $16.29 billion, representing a 4.9% increase year-on-year and exceeding analyst expectations by 3%. The company also delivered a beat on earnings per share estimates. Robert M. Davis, chairman and chief executive officer, emphasized the company's strategic direction: "We are moving with speed to transform our portfolio to one with a diversified set of growth drivers across a broad set of therapeutic areas." Merck's stock has risen 12.3% since the earnings release, trading at $124.64.
Supernus Pharmaceuticals: Strong Top-Line Growth, EPS Miss
Supernus Pharmaceuticals, which maintains a diverse portfolio of eight FDA-approved medications targeting neurological conditions including epilepsy (搜索), ADHD (搜索), Parkinson's disease (搜索), and migraine (搜索), reported revenues of $207.7 million — a 38.6% increase year-on-year that beat analyst expectations by 7.7%. Jack Khattar, President and CEO of Supernus, highlighted that "Our first quarter results reflect a strong start to the year, including a 56% year-over-year increase in combined revenues of our growth products." Despite the revenue beat, the quarter was mixed, with full-year operating income guidance only slightly topping expectations while EPS estimates were significantly missed. The stock declined 9.6% following the report, trading at $44.47.
Sector Headwinds and Tailwinds
The branded pharmaceutical industry faces a complex landscape. Tailwinds include advancements in precision medicine, increasing adoption of AI to enhance drug development efficiency, and growing global demand for treatments addressing chronic and rare diseases. However, headwinds persist in the form of heightened regulatory scrutiny, pricing pressures from governments and insurers, and looming patent cliffs for key blockbuster drugs — which invite generic competition and force companies to continually replenish their pipelines.
Other Notable Performances
Bristol-Myers Squibb reported revenues of $11.49 billion, up 2.5% year-on-year, topping analyst expectations by 7.4% with a beat on EPS estimates but a slight miss on full-year EPS guidance. Corcept Therapeutics posted revenues of $164.9 million, up 4.9% year-on-year, though results came in 11.3% below analyst expectations. Zoetis, the animal health company spun off from Pfizer, recorded revenues of $2.26 billion, up 2.9% year-on-year but falling short of estimates by 2.1%, marking it as the weakest performer of the quarter with its stock down approximately 31.5% to 31.6%.